The Company and Summary of Significant Accounting Policies (Details Narrative) - EUR (€)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accumulated deficit	€ (101,648,000)		€ (101,648,000)		€ (97,750,000)
Current liabilities exceeding current assets	€ 70,623		€ 70,623
Preferred stock shares authorized	5,000,000		5,000,000		5,000,000
Potentially shares issuable			793,630,391	757,030,713
Potentially shares issuable convertible loans	767,880,391			731,280,713
Sub award grant revenue USD			€ 971
Sub award grant revenue euro			909
Sub award project cost USD			2,796
Sub award project cost euro			€ 2,511
Basic weighted and diluted	303,757,622	303,757,622	303,757,622	303,757,622
Professional fees	€ 10	€ 6	€ 40	€ 17
Carrying amount			€ 70,603
Budget description			The overall budget related to the project is US$8,850 with US$1,940 approved for the first year, US$1,856 approved for the second year, and US$1,720 for the third year. In April 2022, the Company filed a report to the NIH in collaboration with ULL, to validate funds for the fourth year of the ongoing HIV project (May 2022 to April 2023). The funds for the fourth year were approved in May 2022 with a total budget of US$ 1,616.
Grant allocated description			The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$5,930, with US$1,190 approved for the first year, US$1,052 for the second year, US$ 1,078 for the third year and US$1,328 approved in May 2022 for the fourth year.
Grant Revenue [Member]
Concentration risk percentage			100.00%	99.00%
First Year [Member]
Sub award project cost USD			€ 547
Sub award project cost euro			542
Second Year [Member]
Sub award project cost USD			870
Third Year [Member]
Sub award project cost USD			€ 1,078
Stock Option [Member]
Potentially shares issuable			25,750,000	25,750,000